Gracell Biotech of Suzhou completed a $209 million NASDAQ IPO for its next-get CAR-T treatments. Gracell set out to address the difficulties presented by previous cell therapies, including complex manufacture, lack of off-the-shelf products and the short duration of efficacy. Gracell uses two platforms for discovery: FasTCAR, which manufactures autologous CAR-T products in 22-36 hours (rather than two to six weeks); and TruUCAR, which offers off-the-shelf CAR-T products. Gracell has a market cap of $1.7 billion after climbing 38% in early trading. More details.... Stock Symbol: (NSDQ:GRCL) Share this with colleagues: // //